Abstract: A system and method for intelligent message routing is provided. The system and method include a) receiving a first message to be transmitted to a participant, wherein the first message includes a first conversation identifier signifying a first conversation with the participant, b) determining a first channel to transmit the first message to the participant, c) transmitting the first message over the first channel; and d) locking the first channel to the first conversation.

Abstract: A system that allows for channel and platform agnostic automated scheduling. A user that is registered with the system may add an automated assistant into a pre-existing communication thread or channel, such as a short messaging service (“SMS”) conversation between multiple friends. Any user in the thread may interact with the assistant even if not registered with the system. Once present, the assistant analyzes messages sent to the thread for wake words that trigger actions or responses by the system, including automated scheduling actions. When scheduling is invoked, the system will find acceptable times based on top-down and bottom-up availability provided by registered users, and will propose meeting times until one is accepted by some or all of the participants. Once accepted, the system will confirm the meeting, update linked calendars, and provide reminders to attendees.

Abstract: Aspects of the disclosure relate to pre-format embeddings used for model training, and in particular, training of dual encoder LLMs. For instance, a dataset batch of pairs of input text and one or more classification labels may be accessed. A unique identifier to each pair of input text and one or more classification labels may be assigned. The pairs of input text and one or more classification labels and assigned unique identifiers may be used to train a model to assign classification labels to textual inputs.

Abstract: Provided is a chimeric antigen receptor targeting CLL1 and an application thereof. The chimeric antigen receptor targeting CLL1 comprises an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain; the antigen binding domain is an anti-CLL1 antibody. The present application uses an anti-CLL1 antibody as the antigen binding domain to construct a chimeric antigen receptor molecule, the chimeric antigen receptor targeting CLL1 has specific targeting effect on CLL1 positive tumor cells, and immune cells expressing chimeric antigen receptor targeting CLL1 have a significant killing effect in vitro and in vivo, and secrete a large amount of cytokine IFN-? after co-cultured with CLL1 positive tumor cells, which has a specific clearance effect on CLL1 positive tumor cells.

Abstract: An unnatural amino acid, where the unnatural amino acid is a compound with a structure as shown in formula (I) or an enantiomer thereof, where X represents —O—, —S—, —NH— or —CH2—, Y represents —O—, —S—, —C(O)—, —S(O)— or —CH2—, and L represents substituted or unsubstituted C0-C20 linear or branched alkylene, where one or more —CH2— are optionally substituted by one or more of —O—, —S—, —NH—, —C(O)— and —S(O)—, when X represents —O— and Y represents —C(O)—, L does not represent —CH2CH2—, and when L represents a substituent, the substituent is selected from one or more of hydroxyl, sulfhydryl, halogen, nitro, cyano, alkyl, alkenyl, alkynyl, alkoxy, acyl, acylamino, carboxyl, ester, amino, sulfonyl, sulfinyl, cycloalkyl, heterocyclyl, aryl and heteroaryl.

Abstract: Provided is an anti-CLL1 antibody and an application thereof. The variable region of the anti-CLL1 antibody includes the CDRs of SEQ ID NO: 1 to 6, SEQ ID NO: 5, and SEQ ID NO: 7 to 11 or SEQ ID NO: 12 to 17. The anti-CLL1 antibody of the present application has significant binding ability to both free and cell surface CLL1. After humanization, the affinity of the antibody to CLL1 is further improved, and it has important application prospect in the clinical diagnosis and/or treatment of tumors.

Abstract: A human interleukin 2-polyethylene glycol conjugate and use thereof. The human interleukin 2-polyethylene glycol conjugate comprises a recombinant human interleukin 2 containing at least one unnatural amino acid and PEG coupled to the at least one unnatural amino acid. The unnatural amino acid is a compound containing a carbonyl terminal group and having a structure as shown in formula (I) or an enantiomer thereof, and the PEG is coupled to the at least one unnatural amino acid by forming an oxime bond between the carbonyl terminal group and the PEG containing a hydroxylamine terminal group. The human interleukin 2-polyethylene glycol conjugate can be used individually or in combination with other anti-tumor drugs for the treatment of diseases such as solid tumors and hematologic tumors.

Abstract: The invention provides a human interleukin 2-polyethylene glycol conjugate and use thereof. The human interleukin 2-polyethylene glycol conjugate provided by the invention comprises a recombinant human interleukin 2 containing at least one unnatural amino acid and PEG coupled to the at least one unnatural amino acid. The unnatural amino acid is a compound containing a carbonyl terminal group and having a structure as shown in formula (I) or an enantiomer thereof, and the PEG is coupled to the at least one unnatural amino acid by forming an oxime bond between the carbonyl terminal group and the PEG containing a hydroxylamine terminal group. The human interleukin 2-polyethylene glycol conjugate provided by the invention can be used individually or in combination with other anti-tumor drugs for the treatment of diseases such as solid tumors and hematologic tumors.

Abstract: A system and method for intelligent message routing is provided. The system and method include a) storing, in one or more storage devices, a plurality of transmission rules for transmitting messages, b) receiving a message to be transmitted to a participant, c) comparing the message to the plurality of transmission rules, d) determining a first channel to transmit the message to a computer device associated with the participant based on the comparison, e) converting the message into a first message for transmission on the first channel, and f) transmitting the first message over the first channel.

Abstract: The present invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to a 1-aminobenzo[4,5]imidazo[1,2-a]pyrazine-3-formamide compound, and the preparation therefor and use thereof. The structure of the compound of the present invention is as shown in formula (I). The compound has a novel structure and is an adenosine receptor inhibitor, has good inhibitory activity on adenosine A2A receptors, has good subtype selectivity, and can be used as a targeted adenosine A2A receptor inhibitor for immunotherapy. By means of inhibiting the activity of the adenosine A2A receptor, the function of removing tumor cells by the immune system is released, so that the effect of treating tumors is achieved.

Abstract: An unnatural amino acid may have a structure as shown in formula (1) or may be an enantiomer thereof: Such unnatural amino acid may be used, e.g., in recombinant proteins. A recombinant protein may contain such unnatural amino acid and a protein conjugate prepared from the recombinant protein. The unnatural amino acid can be simple and convenient to prepare, safe in nature, difficult to inactivate when inserted into a protein, and may have a high binding rate with a coupling moiety, and the obtained conjugate is higher in stability. The unnatural amino acid is applicable to numerous fields, especially in preparation of a recombinant protein or a recombinant protein conjugate.

Abstract: A system that allows for channel and platform agnostic automated scheduling. A user that is registered with the system may add an automated assistant into a pre-existing communication thread or channel, such as a short messaging service (“SMS”) conversation between multiple friends. Any user in the thread may interact with the assistant even if not registered with the system. Once present, the assistant analyzes messages sent to the thread for wake words that trigger actions or responses by the system, including automated scheduling actions. When scheduling is invoked, the system will find acceptable times based on top-down and bottom-up availability provided by registered users, and will propose meeting times until one is accepted by some or all of the participants. Once accepted, the system will confirm the meeting, update linked calendars, and provide reminders to attendees.

Abstract: A system and method for intelligent message routing is provided. The system and method include a) storing, in one or more storage devices, a plurality of transmission rules for transmitting messages, b) receiving a message to be transmitted to a participant, c) comparing the message to the plurality of transmission rules, d) determining a first channel to transmit the message to a computer device associated with the participant based on the comparison, e) converting the message into a first message for transmission on the first channel, and f) transmitting the first message over the first channel.

Abstract: A system that allows for channel and platform agnostic automated scheduling. A user that is registered with the system may add an automated assistant into a pre-existing communication thread or channel, such as a short messaging service (“SMS”) conversation between multiple friends. Any user in the thread may interact with the assistant even if not registered with the system. Once present, the assistant analyzes messages sent to the thread for wake words that trigger actions or responses by the system, including automated scheduling actions. When scheduling is invoked, the system will find acceptable times based on top-down and bottom-up availability provided by registered users, and will propose meeting times until one is accepted by some or all of the participants. Once accepted, the system will confirm the meeting, update linked calendars, and provide reminders to attendees.

Abstract: A chimeric antigen receptor fusion protein co-expressing IL-7 and CCR2b, and application thereof are provided. The fusion protein includes a chimeric antigen receptor, a 2A peptide, IL-7, a 2A peptide and CCR2b which are sequentially linked in series.

Abstract: A system and method for intelligent message routing is provided. The system and method include a) storing, in one or more storage devices, a plurality of transmission rules for transmitting messages, b) receiving a message to be transmitted to a participant, c) comparing the message to the plurality of transmission rules, d) determining a first channel to transmit the message to a computer device associated with the participant based on the comparison, e) converting the message into a first message for transmission on the first channel, and f) transmitting the first message over the first channel.

Abstract: Provided are an anti-B7H3 chimeric antigen receptor and an application thereof. The anti-B7H3 chimeric antigen receptor comprises an antigen binding domain, a hinge region, a transmembrane domain and a signaling transfer structural domain. The antigen binding domain is an anti-human B7H3 antibody. The anti-B7H3 chimeric antigen receptor has a specific targeting effect on B7H3-positive tumor cells, T cells that express the anti-B7H3 chimeric antigen receptor have significant killing effects in vitro and in vivo, can effectively remove the B7H3-positive tumor cells, and having important significance in the field of tumor therapy.

Abstract: Provided are an anti-Claudin 18.2 antigen-binding fragment or antibody, and the use thereof. CDR3 of a heavy chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 3. CDR3 of a light chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 6. The provided antigen-binding fragment and anti-Claudin 18.2 antibody can specifically bind to a variety of sources of Claudin 18.2 proteins, have no binding effect on other proteins, and have a high specificity. In addition, a chimeric antigen receptor and a CAR-T cell prepared by means of the antibody have obvious cytotoxicity on cells stably expressing the Claudin 18.2 protein.

Abstract: A system and method for intelligent message routing is provided. The system and method include a) storing, in one or more storage devices, a plurality of transmission rules for transmitting messages, b) receiving a message to be transmitted to a participant, c) comparing the message to the plurality of transmission rules, d) determining a first channel to transmit the message to a computer device associated with the participant based on the comparison, e) converting the message into a first message for transmission on the first channel, and f) transmitting the first message over the first channel.

Abstract: A system that allows for channel and platform agnostic automated scheduling. A user that is registered with the system may add an automated assistant into a pre-existing communication thread or channel, such as a short messaging service (“SMS”) conversation between multiple friends. Any user in the thread may interact with the assistant even if not registered with the system. Once present, the assistant analyzes messages sent to the thread for wake words that trigger actions or responses by the system, including automated scheduling actions. When scheduling is invoked, the system will find acceptable times based on top-down and bottom-up availability provided by registered users, and will propose meeting times until one is accepted by some or all of the participants. Once accepted, the system will confirm the meeting, update linked calendars, and provide reminders to attendees.